Notice of Intent to Sole Source for Chemical Compounds

This notice announces the intent by the U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of the U.S. Army Public Health Center (APHC), to purchase the synthesis and delivery of chemical compounds without competition as prescribed in FAR 13.501(a)(1)(i). Specifically, the Government will procure these products from TNO Locatie Rijswijk located at Lange Kleiweg 137, Rijswijk ZH, 2288 GJ, Netherlands, which has access to as well as the ability to synthesize the necessary chemical compounds. The North American Industry Classification System (NAICS) for this requirement is 325998, All Other Miscellaneous Chemical Product and Preparation Manufacturing, and the Product Service Code (PSC) is 6810, Chemicals. This announcement fulfills the synopsis requirements under FAR 5.102(a)(6) and 5.203(a). USAMRAA intends to publish a solicitation no sooner than 15 days after publishing this synopsis. This Special Notice of Intent is not a request for competitive quotes. Information received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. Interested concerns must submit their capability in writing to the email address listed below by the listed due date and time. Submissions that request documentation or request additional information or that only ask questions will not be considered affirmative responses and will not be considered valid. Responses not considered valid will not be evaluated further. If no written responses are received by the date listed below, which reflects at least fifteen (15) days after the publication of this notice, the solicitation will be issued as sole source. All questions and responses concerning this notice shall be emailed to the Contract Specialist, Jesse Nisley, at jesse.d.nisley.civ@health.mil. Submissions shall be received no later than 2:00PM Eastern Time, 02 September 2022. PROGRAM BACKGROUND As the Department of Defense's lead laboratory for the development of medical countermeasures against chemical threat agents, USAMRICD is increasingly called upon to provide expert analytical and consultative services related to medical chemical defense research and to the medical management of chemical casualties. The United States of America is one of the 183 members of the Organisation of the Prohibition of Chemical Weapons (OPCW). The United States of America is also one of the Executive Council members of the OPCW. The OPCW mission is to implement the provisions of the Chemical Weapons Convention to achieve their vision of a world free of chemical weapons and the threat of their use, in which chemistry is used for peace, progress, and prosperity. The current OPCW Programme Aims are 1) Credible and Transparent Regime; 2) Protection and Assistance; 3) International Cooperation; and 4) Universal Membership. As the leading experts in chemical defense and the US Army's dedicated laboratory for expert chemical defense research, the USAMRICD must maintain the highest standards for chemical defense research as well as clinical laboratory and testing capabilities. To ensure these standards are maintained, the USAMRICD Clinical Laboratory, within the Medical Toxicology Research Division, Pharmaceutical Sciences Department, requires annual proficiency checks. One of the auditing mechanisms is the Biomedical Proficiency Testing (BioPT) via OPCW. Historically, the USAMRICD has performed multiple clinical assays on each sample for the proper identification of chemical agent. In keeping with the modernization of military medicine and research in support of the warfighter, USAMRICD has established a new comprehensive assay for the identification of chemical warfare agents, reducing the number of samples and tests required for chemical threat identification. In order for USAMRICD to maintain accreditation as a Clinical Laboratory, assay validation is required. This validation directly supports BioPT and accreditation through OPCW. The USAMRICD Medical Toxicology Research Division has a requirement for the following items: - 10 mg of the tyrosine adduct of GA, O-ethyl-N-dimethylaminophospho-tyrosine, Chemical Abstracts Service (CAS) registry unknown; 90% purity - 10 mg of the tyrosine adduct of GB, IMPA-tyrosine (O-[Methyl(1-methylethoxy)phosphinyl]-L-tyrosine), CAS registry no. 1365420-03-6; 90% purity - 10 mg of the tyrosine adduct of GD, PMPA-tyrosine, CAS registry no. 1365420-06-9 ; 90% purity - 10 mg of the tyrosine adduct of GF, O-cyclohexyl MPA-tyrosine, CAS registry unknown; 90% purity - 10 mg of the tyrosine adduct of ethylsarin (VX), EMPA-tyrosine (O-(Ethoxymethylphosphinyl)-L-tyrosin), CAS registry no. 1365420-08-1; 90% purity - 10 mg of the tyrosine adduct of isobutylsarin (RVX), O-isobutyl MPA-tyrosine, CAS registry unknown; 90% purity - 10 mg of the tyrosine adduct of n-butylsarin (Chinese VX), O-n-butyl MPA-tyrosine, CAS registry unknown; 90% purity - 10 mg of tyrosine adduct of A-230 (methyl-(1 (diethylamino)ethylidene)phosphonamidofluoridate), CAS registry no. of A-230 2387496-12-8; 60% purity - 10 mg of the tyrosine adduct of A-232 (methyl-(1-(diethylamino)ethylidene)phosphoramidofluoridate), CAS registry no. of A-232 2387496-04-8; 60% purity - 10 mg of the tyrosine adduct A-234 (ethyl N-[(1E)-1-(diethylamino)ethylidene]-phosphoramidofluoridate), CAS registry of no. of A-234 2387496-06-0; 60% purity